New scan could reveal hidden joint inflammation in arthritis patients

NCT ID NCT03546335

Terminated Knowledge-focused Sponsor: Robert Flavell, MD, PhD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tests a radioactive imaging agent called 89Zr-Cimzia in 10 people with rheumatoid arthritis. The goal is to see if it can highlight inflamed joints on a PET scan, comparing painful joints to pain-free ones. The study is currently suspended, and it is exploratory, meaning it aims to gather information rather than treat the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 89Zr-DFO-Certolizumab pegol (a radioactive imaging agent)
What this could lead to: If successful, this could lead to a new way to see inflammation in joints using PET scans, helping doctors better understand and monitor rheumatoid arthritis.
What could go wrong: This is a very early, small study with only 10 participants. It is currently suspended, and the imaging agent is experimental. It may not show clear differences between painful and pain-free joints.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS

Contacts and locations

Locations

University of California, San Francisco

San Francisco, California, 94143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.